Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerRafael G Amado, Michael Wolf, Marc Peeters, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2008
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerRafael G Amado, Michael Wolf, Marc Peeters, et al.Cancer Cell|March 7, 2003
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanismsDaniel J Freeman, Andrew G Li, Gang Wei, et al.Ebiomedicine|July 3, 2015
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung CancerJeanne Mendell, Daniel J Freeman, Wenqin Feng, et al.Journal of Medicinal Chemistry|July 1, 2011
Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stabilityMarkian M Stec, Kristin L Andrews, Shon K Booker, et al.Bioorganic & Medicinal Chemistry Letters|July 27, 2012
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffoldRyan P Wurz, Longbin Liu, Kevin Yang, et al.Bioorganic & Medicinal Chemistry Letters|February 9, 2010
Azole-based inhibitors of AKT/PKB for the treatment of cancerQingping Zeng, John G Allen, Matthew P Bourbeau, et al.Cancer Discovery|January 9, 2021
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T CellsSimon J Dovedi, Matthew J Elder, Chunning Yang, et al.Journal of Medicinal Chemistry|May 3, 2012
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinasesAdrian L Smith, Noel D D'Angelo, Yunxin Y Bo, et al.Journal of Medicinal Chemistry|August 18, 2012
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511Mark H Norman, Kristin L Andrews, Yunxin Y Bo, et al.Pageof 2